doctoralThesis
Análise das demandas judiciais por medicamentos no Estado do Rio Grande do Norte
Fecha
2020-07-24Registro en:
OLIVEIRA, Yonara Monique da Costa. Análise das demandas judiciais por medicamentos no Estado do Rio Grande do Norte. 2020. 110f. Tese (Doutorado em Saúde Coletiva) - Centro de Ciências da Saúde, Universidade Federal do Rio Grande do Norte, Natal, 2020.
Autor
Oliveira, Yonara Monique da Costa
Resumen
The judicialization of health, especially in access to medicines, is a complex and multifactorial
phenomenon that involves technical-scientific, legal, economic and social aspects, and may
have different implications for public health. With the constitutional recognition of health as a
right and the implementation of the Unified Health System (Sistema Único de Saúde - SUS),
an increasing number of citizens have sought the Judiciary to guarantee the constitutional
promise, and the number of lawsuits has grown over the years. As a relevant question, the theme
of judicialization has been debated in several spaces: in society, in academia, by legal
institutions and by health managers. However, it has not yet been possible to draw a national
panorama of the judicialization of medicines in Brazil, with a marked concentration of research
in the Southeast and South regions of the country. In this context, the aim of this study was to
identify and analyze the lawsuits for medicines in the State of Rio Grande do Norte, describing
the sociodemographic, medical-sanitary and judicial characteristics of the processes, making an
analysis in the light of current drug policies and evaluating its possible interfaces with the
process of incorporating technologies into SUS. It was conducted a descriptive, exploratory and
retrospective, whose unit of analysis was the individual processes requesting medicines from
the State of Rio Grande do Norte, between the years 2013 to 2017. The data were collected
from the State Department of Public Health (SESAP/RN), and the information on the cases was
collected through consultation with the website of the Court of Justice of RN. Nine hundred
eighty-seven (987) processes were analyzed, in which 1517 medicines were requested. Most of
the claimants were female (58.8%), residing in the interior of the State, with an average age of
48.3 years, represented predominantly by public legal assistance (52.8%) and with prescription
from private medical services (38.1%). Most of the requested drugs (61.7%) were not
incorporated into SUS, however, in 75% of the cases, there was a therapeutic alternative. In
13.6% of the actions, at least 1 medicine was prescribed for off-label use. Even the judicialized
drugs that were part of the National List of Essential Medicines (Rename), were constantly
requested for indications not recommended in official protocols. In 68% of the cases, access to
the drug was available, with the author responsible for the purchase in 56.1% of them, through
blocking public funds. The most requested medicine was insulin glargine (74 lawsuits). Drugs
not available in SUS and frequently requested in court demands tend to be incorporated later,
becoming part of health policy. Of the 10 drugs with the highest number of lawsuits, 4 were
subsequently incorporated into SUS, mainly insulin analogues. Regarding the process of
incorporating these drugs, it was observed that internal demands predominated (60%), and the
minority had economic assessments (40%), the main justification used to support decisions
being the presence of scientific evidence. However, a change of position was observed after the
expressive participation in public consultations and the judicialization of medicines is
mentioned in some reports. The results showed that the judicial system has been consolidated
as a way of accessing medicines in Rio Grande do Norte, including by citizens residing in the
interior of the State, who obtain free legal assistance. The most of the drugs requested were not
yet incorporated into SUS, and these requests frequently violated health and Pharmaceutical
Assistance management rules. The blocking of public funds for the fulfillment of these
decisions is another worrying factor for the SUS manager, as it compromises the execution of the programmed medicines policies, which impair their execution. In the process of
incorporating drugs targeted by lawsuits, it was observed that despite the preponderance of the
technical-scientific basis in decisions to incorporate drugs into SUS, there was an indirect
influence of judicialization in the decision-making process.